SRI has developed a promising new treatment for this cancer of the immune system that affects plasma cells in bone marrow.
SRI’s Brown Laboratory is utilizing cell-targeting peptides to deliver active therapeutic cargo to specific cells in vivo.
SRI’s Brown Laboratory is using selected peptides as “fishing hooks” to identify novel cell surface features.
SRI is developing a new therapeutic agent for influenza virus infections.
SRI's Brown Laboratory is taking multiple approaches to develop effective anti-cancer immunotherapies.
SRI is analyzing the genetics of smoking and related characteristics, using data from a large-scale National Cancer Institute study on smoking cessation.
Using synthetic lethality to ID biomarkers for targeted anti-cancer drugs.